Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing open-label single-arm study of sotatercept added to background therapy in Chinese patients with pulmonary arterial hypertension
CTR20263942Phase 4Active
- Sponsor
- Merck & Co.
- Start
- Oct 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of sotatercept in pulmonary arterial hypertension (PAH), sponsored by Merck & Co.. Started Oct 2026; status: active.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on CTR20263942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263942.